PMNProMIS Neurosciences Inc.

Nasdaq promisneurosciences.com


$ 1.27 $ -0.07 (-5.34 %)    

Wednesday, 18-Sep-2024 14:10:29 EDT
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 1.24
$ 1.27
$ 1.33 x 100
-- x --
$ 1.27 - $ 1.27
$ 0.95 - $ 3.10
31,415
na
37.06M
$ 17.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 04-01-2024 12-31-2023 10-K
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 promis-neurosciences-reveals-data-on-the-pathogenic-role-of-toxic-misfolded-sod1-aggregates-in-als

Body of work supports targeting misfolded proteins as a therapeutic strategy for ALS with the potential to translate across mul...

 promis-neurosciences-reports-top-line-data-from-the-first-four-cohorts-of-its-first-in-human-phase-1a-clinical-trial-of-pmn310-in-healthy-volunteers-for-alzheimers-disease-patients-topline-results-demonstrated-a-favorable-safety-profile-and-tolerability-across-four-ascending-dose-levels

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteer...

 promis-neurosciences-announces-up-to-1227m-private-placement-financing-proceeds-expected-to-support-company-beyond-6-month-and-12-month-data-from-the-pmn310-phase-ib-study-in-alzheimers-patients

$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warran...

 promis-neurosciences-q1-2024-adj-eps-019-beats-020-estimate

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $...

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

 dow-jumps-over-300-points-goldman-sachs-posts-upbeat-earnings

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.8...

 promis-neurosciences-q4-eps-009-beats-017-estimate

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $...

 promis-neurosciences-reveals-strengthening-of-global-intellectual-property-portfolio

The European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed compos...

 why-transcode-therapeutics-shares-are-trading-lower-by-over-24-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,...

 promis-neurosciences-q3-eps-019-up-from-085-yoy

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.19) per share. This is a 77.65 percent increase over losses ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION